股息配發率   玩股撇步(動畫小學堂)

  • 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
  • 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
  • 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY現金股利 YoY股票股利 YoY現金配發率 YoY股票配發率 YoY全部配發率 YoY
2023 (10)-1.4700.0000.0000.0000.0000.000
2022 (9)-3.0500.0000.0000.0000.0000.000
2021 (8)0.6400.0000.0000.0000.0000.000
2020 (7)-2.6700.0000.0000.0000.0000.000
2019 (6)-2.0500.0000.0000.0000.0000.000
2018 (5)-0.5100.0000.0000.0000.0000.000
2017 (4)-2.2400.0000.0000.0000.0000.000
2016 (3)-2.6400.0000.0000.0000.0000.000
每股盈餘-近20季
EPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY
23Q4 (20)-0.696.76-387.5-0.62-19.23-93.75-1.47-90.9151.8
23Q3 (19)-0.7420.4322.11-0.5222.390.0-0.77-2466.6776.6
23Q2 (18)-0.93-204.4922.5-0.67-52.27-8.06-0.03-103.3798.72
23Q1 (17)0.89270.83178.07-0.44-37.5-18.920.89129.18178.07
22Q4 (16)0.24125.26111.01-0.3238.4665.59-3.057.29-576.56
22Q3 (15)-0.9520.83-130.65-0.5216.1318.75-3.29-40.6-216.25
22Q2 (14)-1.20-5.26-62.16-0.62-67.57-8.77-2.34-105.26-680.0
22Q1 (13)-1.1447.71-347.83-0.3760.2228.85-1.14-278.12-347.83
21Q4 (12)-2.18-170.32-211.43-0.93-45.31-111.360.64-77.39123.97
21Q3 (11)3.10518.92875.0-0.64-12.28-18.522.831043.33240.1
21Q2 (10)-0.74-260.87-10.45-0.57-9.62-32.56-0.30-165.2281.48
21Q1 (9)0.46165.71148.42-0.52-18.1824.640.46117.23148.42
20Q4 (8)-0.70-75.014.63-0.4418.52-246.67-2.67-32.18-30.24
20Q3 (7)-0.4040.340.3-0.54-25.58-45.95-2.02-24.69-62.9
20Q2 (6)-0.6729.47-658.33-0.4337.68-4.88-1.62-70.53-184.21
20Q1 (5)-0.95-15.85-37.68-0.69-330.0-30.19-0.9553.66-37.68
19Q4 (4)-0.82-22.390.00.30181.080.0-2.05-65.320.0
19Q3 (3)-0.67-658.330.0-0.379.760.0-1.24-117.540.0
19Q2 (2)0.12117.390.0-0.4122.640.0-0.5717.390.0
19Q1 (1)-0.690.00.0-0.530.00.0-0.690.00.0
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2024/30.0837.53.30.04-44.040.04N/A-
2024/20.0-99.01-98.680.04-46.290.13N/A本月銷貨及勞務收入皆較去年同期減少
2024/10.04-54.83-11.40.04-11.40.23N/A-
2023/120.09-12.66-0.630.58112.930.195.4本年度累積銷貨收入及勞務收入皆較去年度增加。
2023/110.125555.06880.950.49169.580.119.71本月勞務收入較去年同期增加;本年度累積銷貨收入及勞務收入皆較去年度增加。
2023/100.0-90.09-99.290.38114.570.0813.11本月銷貨收入及勞務收入皆較去年同期減少;本年度累積銷貨收入較去年度增加。
2023/90.0-94.6174.820.38212.820.166.33本月銷貨收入及勞務收入皆較去年同期增加;本年度累積銷貨收入及勞務收入皆較去年度增加。
2023/80.07-10.6226.980.38213.30.176.12本月銷貨收入較去年同期增加
2023/70.08773.4290.120.31210.160.25.23本月銷貨收入較去年同期增加
2023/60.01-90.73-59.430.22187.890.147.32本月銷貨收入較去年同期減少;本年度累積銷貨收入及勞務收入皆較去年度增加。
2023/50.1257.8617155.00.21297.360.147.64本月銷貨收入較去年同期增加
2023/40.03696.9616.510.11105.810.0616.51本年度銷貨及勞務收入皆較去年增加
2023/30.0-88.07159.280.08185.060.0813.17本月勞務收入較去年同期增加
2023/20.03-33.3921.380.08186.380.176.31本年度銷貨及勞務收入皆較去年增加
2023/10.05-49.342925.820.052925.820.147.64本月銷貨及勞務收入皆較去年同期增加
2022/120.096035.37-6.680.2751.140.157.36本年度銷貨收入及勞務收入皆較去年度增加
2022/110.0-97.39-65.730.18118.740.0618.35本月勞務收入較去年同期減少
2022/100.063740.81943.620.18128.840.0813.49本月銷貨收入及勞務收入皆較去年同期增加
2022/90.0-93.58600.00.1268.430.0524.21本月勞務收入較去年同期增加
2022/80.026.66287.470.1266.890.0716.32本月銷貨收入及勞務收入皆較去年同期增加
2022/70.02-9.1710123.80.147.370.0524.28本月勞務收入較去年同期增加
2022/60.023840.09.240.0815.620.0519.77-
2022/50.0-97.58185.710.0518.680.0336.15本月勞務收入較去年同期增加
2022/40.021673.5714.740.0517.90.0518.91-
2022/30.0-94.41102.890.0320.860.0332.88本月勞務收入較去年同期增加
2022/20.031560.2612.110.0318.340.127.47-
2022/10.0-98.431410.00.01410.00.18.98本月勞務收入較去年同期增加
2021/120.12152.91-28.520.18-17.170.117.71-
2021/110.0-20.73800.00.081.710.0182.74本月勞務收入較去年同期增加
2021/100.012476.194818.180.08-3.430.0171.12本月勞務收入較去年同期增加
2021/90.0-96.44110.00.07-9.980.01105.85本月勞務收入較去年同期增加
2021/80.012714.28-57.140.07-10.120.0324.14本月銷貨收入較去年同期減少
2021/70.0-99.02110.00.07-0.470.0230.37本月勞務收入較去年同期增加
2021/60.0210204.8-0.50.07-0.640.0415.64-
2021/50.0-99.02-32.250.04-0.70.0230.17-
2021/40.023036.23-2.160.04-0.480.0415.22-
2021/30.0-96.910.00.021.130.0230.67-
2021/20.0222260.04.00.021.170.164.5-
2021/10.0-99.92-85.710.0-85.710.145.24勞務收入較去年同期減少
2020/120.14122836.0-90.820.22-87.410.142.36授權金收入較去年同期減少
2020/110.00.0-99.890.08-67.020.01000.0LT3001授權收入較去年同期減少
2020/100.010.0-99.50.08-41.520.0122.86本月LT1001藥品銷售收入較去年同期減少
2020/90.0-99.27-79.590.08-30.530.0125.02本月勞務收入較去年同期減少
2020/80.0113690.0-34.480.08-30.330.049.82-
2020/70.0-99.54-79.590.07-29.410.0215.79本月勞務收入較去年同期減少
2020/60.026916.12-0.450.07-29.150.047.24-
2020/50.0-98.590.00.05-37.760.0213.84本月勞務收入較去年同期增加
2020/40.023105.790.00.05-38.190.047.22本月LT1001藥品銷售收入及勞務收入較去年同期增加
2020/30.0-96.79-94.690.02-68.560.0215.29勞務收入減少
2020/20.022971.42-23.320.02-62.881.50.23去年營收主要為生物藥技術服務收入
2020/10.0-99.95-97.790.0-97.791.580.22去年營收主要為生物藥技術服務收入3,153
2019/121.471268.821460.061.72183.831.60.15108/12認列止痛藥之簽約金收入及中風專案之里程金收入
2019/110.11387.0116.340.25-51.820.131.84LT1001授權收入減少
2019/100.024412.244506.250.14-66.880.045.52018/8 簽約金及里程碑收入
2019/90.0-97.674.250.12-72.120.026.352018/8 簽約金及里程碑收入
2019/80.024195.91-93.540.12-72.20.043.23107年8月為簽約金及里程碑收入
2019/70.0-97.754.250.13.60.026.27-
2019/60.020.04452.080.093.60.022.29銷貨收入增加
2019/50.00.0-100.00.07-19.880.0N/A勞務收入減少
2019/40.0-100.0-100.00.07-19.470.0N/A勞務收入減少

股利相關資訊

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。